Covid-19 News and Discussions

@Sharma Ji


Thousands seek compensation after Covid vaccines ‘left them disabled’​

Payments have been awarded for conditions including stroke, heart attack, blood clots, inflammation of the spinal cord and facial paralysis

Sarah Knapton, SCIENCE EDITOR 17 August 2024 • 1:03pm

Related Topics

2576


Leona Sanders, 52, was left hospital-bound after three jabs

Leona Sanders was left hospital-bound after three jabs. Her husband Seb, a champion flat race jockey, has been fighting on her behalf
Nearly 14,000 people in Britain have applied for payments from the government for alleged harm caused by Covid vaccines, new figures show.

Freedom of Information requests made by The Telegraph show that payments have already been awarded for conditions including stroke, heart attack, dangerous blood clots, inflammation of the spinal cord, excessive swelling of the vaccinated limb and facial paralysis.

Around 97 per cent of claims awarded relate to the AstraZeneca jab, with just a handful of payments made for damage from Pfizer or Moderna.

Since the Vaccine Damage Payment Scheme (VDPS) was founded in 1979 it has had around 16,000 applications, but the Covid jab has made up the vast majority of claims.

Seb Sanders, the British champion flat race jockey, has been fighting on behalf of his wife, Leona, who was left hospital-bound after three Covid jabs, but their claim was rejected.

Mrs Sanders, 52, who suffered from the rare autoimmune disorder granulomatosis - which causes inflammation of the blood vessels - was told the jab would not interfere with her condition and, if anything, would be ineffective, because of her impaired immune system.

She had her first AstraZeneca jab in February 2021, followed by a booster in April.

“It was only a day or two after that she collapsed in the bathroom, her left leg had given way, but we weren’t blaming the injection because nobody had warned us, so we never put two and two together,” said Mr Sanders, who is now a pundit for Sky Sports Racing.

Rapid deterioration after third jab​

However Mrs Sanders’ condition rapidly deteriorated after a third vaccine - this time Pfizer - in December, when paralysis started to move upwards from her feet.

She was admitted to Addenbrooke’s Hospital in Cambridge, where a scan revealed transverse myelitis, a swelling on the spinal cord, which is a known side-effect of the vaccine.

The condition left her unable to walk for seven months and in spite of a brief remission in the summer of 2022, her condition has continued to deteriorate, exacerbated by picking up Covid and developing sepsis while in hospital.

“The collapses all came just days after she had the vaccine,” said Mr Sanders. “But the medical assessor rejected the claim.

“The medical notes said she had a history of back pain and multiple falls, but Leona never complained about back pain or had falls before the jab. She was very active, always with the horses. She never sat down.

“It’s flawed me. I don’t like being made to feel like I am a liar.”

Mr Sanders, a father of one, from Bury St Edmunds, West Suffolk, added: “Before this I would have been sceptical too about vaccines causing harm. But I go to the supermarket now, and I see all the people walking around normally, and that’s when it really hits home. It’s just not right or fair.

“I’m bringing Leona home, but the prognosis for recovery is slim. We’ll take it day-by-day, but all of this needs looking into properly. The collapses all came just days after she had the vaccine.”

Despite warnings and the growing number of clotting cases, the UK government continued to recommend the AstraZeneca jab, even though vaccination had already been halted in Germany, Italy, France, Spain, Denmark, Norway, The Netherlands, Sweden and Latvia by March 2021.

Thousands of people have been turned down by medical assessors who say there is no concrete proof that the vaccine caused harm, while hundreds of others have been refused payment because they are “not disabled enough”.

Those who are successful receive a one-off payment of £120,000, but so far, the government has made payments in just 175 cases, fewer than two per cent of people who have applied.

More than 5,500 claims have been rejected, while a further 519 were dismissed before a medical assessment. Despite nearly 1,000 people asking for their cases to be reconsidered, just 12 have been told their decision has been reversed and they will receive a payment.

Nearly 350 claims were rejected because, although assessors accepted the vaccine had caused harm, they ruled it had not “caused severe disablement”. Under the rules, applicants must be 60 per cent disabled to qualify.

The government insists that the VDPS payment is not a compensation scheme, and the money can be used to help claimants chase damages in court.

However, many argue that the VDPS payment is enough to take on big pharmaceutical companies or compensate for the loss of loved ones.

Many millions of people have had the vaccine without suffering complications and modelling has suggested that vaccines may have saved 1.5 million lives in Europe, and that the death toll could have reached four million without the jabs.

Last year, AstraZeneca officially admitted that in some cases the vaccine can cause VITT and in May it began the worldwide withdrawal of the jab, claiming that it was no longer the most effective now that newer vaccines had been adapted to target Covid-19 variants.
Gareth Eve's wife Lisa Shaw died from vaccine-induced immune thrombocytopenia

Gareth Eve's wife Lisa Shaw died from vaccine-induced immune thrombocytopenia
However AstraZeneca was granted legal indemnity early in the pandemic, so even if a civil case was successful, UK taxpayers would have to pay compensation.

The number of claims has reached such levels that administrative staff processing claims was increased from four to 80 last year. More than 700 people have been waiting over a year for a decision.

A spokesman for the NHS Business Services Authority, which runs the VDPS, said: “The Department of Health and Social Care (DHSC) is responsible for the policy and legislation that governs the VDPS, including the criteria around severity of disablement

“Since taking over the management of the scheme in 2021, the NHSBSA’s dedicated VDPS team works hard to do all we can to support claimants and to actively make improvements to the claim process. We continually review our processes to further develop the way in which we manage claims, and to provide a better service for claimants.”

A spokesman for AstraZeneca said: “Our sympathy goes out to anyone who has lost loved ones or reported health problems.

“Patient safety is our highest priority. From the body of evidence in clinical trials and real-world data, the Oxford-AstraZeneca vaccine has continuously been shown to have an acceptable safety profile and regulators around the world consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects.

“We are incredibly proud of the role Oxford-AstraZeneca played in ending the global pandemic. According to independent estimates, over six million lives were saved in the first year of use alone and over three billion doses were supplied globally. Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic.”

A Pfizer spokesman said: “Patient safety is paramount and we take any reports of adverse events very seriously. Adverse event reports do not imply causality, and in the context of vaccination such events may be unrelated to administration of the vaccine. Hundreds of millions of the Pfizer-BioNTech COVID-19 vaccine have been administered globally and the benefit-risk profile of the vaccine remains positive for all authorised indications and age groups.

“As with every medicine and vaccine, including the Pfizer-BioNTech COVID-19 vaccine, Pfizer has robust processes to meet its regulatory responsibilities to closely monitor, report and analyse all adverse events, and collect relevant information to assess any new potential safety risks that may be associated with the COVID-19 vaccine.

“In addition to our pharmacovigilance efforts and compliance with regulatory requirements related to quality and safety, we also work with regulatory authorities around the world as they independently monitor the safety profile of our vaccine.”

A government spokesman said: “The 60 per cent disablement threshold is aligned to the definition of ‘severe disablement’ consistent, with the Department for Work and Pensions Industrial Injuries Disablement Benefit.

“In the case that an individual’s application is turned down on the basis of disability threshold, there is the option for claimants to appeal the decision.”
 
Last edited:

Dr. Scott Atlas on Why We Were Forced to Jab & Mask​


 

Google AI cannot find a single COVID vaccine success story​

If the COVID vaccine is so darn effective, why are there no success stories? If it worked, the biggest impact would be in the nursing homes. Every nursing home should be a success story, right?​


Steve Kirsch
Aug 18, 2024
367
153
Share

Executive summary​

The reason we never hear about COVID vaccine success stories in nursing homes is because the vaccine rollout was a train wreck and increased all-cause mortality.

Background​

I just made the following query:



Let’s examine the three excuses it gave for its inability to answer a simple question:

  1. This is not true. The case fatality rate information for each facility is publicly reported and available to the public.
  2. Not true. My query was just asking if the CFR dropped. If the vaccine worked, then nearly every nursing home in the US would be a success story. So they wouldn’t be hard to find at all. It should require, on average, one phone call.
  3. I didn’t say I’d judge the program based on a single success anecdote. I just asked for the name of a place where there was a documented success.

Do you have a success or failure story for a US Nursing home you’d like to share? Let me know in the comments!​

If you personally know of a COVID vaccine success OR failure story in a US nursing home facility, please let me know in the comments.

Please talk about the COVID case fatality rate before vs. after the vaccine rollout. Include the name of the facility and the before/after case fatality numbers.

So I need the death/cases ratio, not just deaths.

However, since most facilities have a relatively stable population, just providing all-cause deaths per month BEFORE shot rollout vs. all-cause deaths after shot rollout would work as well.

Thanks!


POLL

If you have personal experience with a nursing home before vs. after the COVID vaccine, did the vaccine save lives?​

Better (worked)
Same (did nothing)
Worse (backfired)
Just want to see answer
854 VOTES · 2 DAYS REMAINING

Summary​

The reason that there isn’t a real-world success anecdote is because the COVID shots didn’t work.

Only in the fantasy world of papers in the peer-reviewed journals did the COVID vaccines save lives.
 

Traces of Covid-19 virus surge in wastewater in S. Korea amid summer wave​

Posted By: Gopi August 18, 2024

Traces of Covid-19 virus surge in wastewater in S. Korea amid summer wave

Seoul, Aug 18 (SocialNews.XYZ) South Korea's disease control agency on Sunday said the level of the Covid-19 virus in wastewater has nearly doubled in just a week, following a surge in infections during the summer vacation season.

According to the Korea Wastewater Surveillance programme, run by the Korea Disease Control and Prevention Agency (KDCA), the average concentration of the virus at local sewage treatment plants reached 47,640 copies per millilitre during the second week of August, Yonhap news agency reported.














Handsfield











It sharply rose from the 24,602 copies per millilitre recorded the previous week.

The data is based on the levels of the Covid virus in water treated by 84 wastewater plants across the country.

The KDCA has used the method since April last year to assess the number of Covid patients within communities.

"The project aims to track the trend in the level of Covid-19 virus in wastewater, which has been rising recently," a KDCA official said.

Meanwhile, the number of newly hospitalised Covid-19 patients in South Korea reached 1,359 during the second week of August, increasing sharply from 878 a week earlier.

With the advent of the Omicron variety, the virus has become an extremely skilled spreader, it is not just a South Korean trend but a worldwide one.

Additionally, after their most recent infection or booster shot, people are more prone to contracting an infection again rather quickly. This is due to two factors: the virus's ongoing evolution, which enables it to infect humans despite having many layers of protection, and the fact that immunity to SARS-2 infections naturally waned over weeks and months.


Individuals with very mild cases may also not have a robust immune response, which means that when they re-expose to the virus, their bodies won't be as well-prepared.

Source: IANS
 

Sunday's Pandemic Update: Most Of The US Remains High For Covid​


 

COVID-19 cases on the rise as students prepare to return to school​


 

FDA set to sign off on updated COVID-19 vaccines​


 

Yuma sees a recent rise in COVID cases​


 

Covid-19: Health Minister says situation in Malaysia under control, no surge in cases​


 

Albany Med study identifies "footprint" of long COVID in blood DNA​

WAMC Northeast Public Radio | By Lucas Willard
Published August 18, 2024 at 12:35 PM EDT
Listen • 10:40
Dr. Ariel Jaitovich

Lucas Willard
/
WAMC
Dr. Ariel Jaitovich
The cause of long COVID, where patients experience symptoms months after their initial illness, is a mystery. Now, a new study might bring scientists a step closer toward understanding the disease.

A pulmonologist from Albany Medical Center finds in a new study that Long COVID appears to be a single disease and not an aggregation of multiple conditions.

Study author Dr. Ariel Jaitovich says additional, wider studies are needed, but the findings could lead to better diagnoses of Long COVID, gauging its severity, and aiding in treatment.

The study was published in this month’s issue of the peer-review eBioMedicine journal. WAMC’s Lucas Willard spoke with Dr. Jaitovich about his research:

The symptoms of acute COVID are not generally the symptoms of long COVID. Patients with acute COVID develop a flu-like condition with fevers and muscle and joint pains. It could be cough, shortness of breath, mainly something like a flu-like condition. That has nothing to do with long COVID. Long COVID is as if the patient has been drained out of energy. So, there is no capacity for the patient to execute their activities, their normal activities, including thinking or breathing or moving, because they feel that they run out of batteries.

Has it been until now, perhaps, unclear about what exactly caused long COVID? Were there ideas about there could be other diseases in the body or other infections? Could the immune system be weakened and the body is affected by other things? Has it essentially been unclear about what's caused long COVID?

So, for full disclosure, it is still unclear what causes long COVID. I don't think that I am in a position to say that I found a final answer, whatsoever. But, like you said, there are many ideas that had been postulated as of why long COVID occurs, including the remaining existence of a virus that was not fully eliminated by the body and remains in a very, kind of, undetectable range, yet present. Also, there is an idea that the virus caused a certain insult to the body, to which the body overreacted and built up, kind of, an overdrive, low intensity immune dysregulation, leading to those conditions, and many others. One of the limitations of the research conducted is that it has been mainly focused on symptom-specific. So, for example, there are some ideas of what could be causing shortness of breath or what could be causing muscle weakness, but not something that is a universal signature of long COVID. And that is a very significant limitation, because in the medical conversation, there is this idea that is floating around that is, ‘Well, yes, acute COVID is one disease, and then that disease leads to complications or some kind of lingering issues that are very diverse and somewhat disconnected from each other.’ Similarly, for example, to the post critical illness syndrome. So, a patient goes to the ICU because it's very sick and survives the hospitalization. The patient can develop skin pressure sores. It can develop kidney failure, it can develop cognitive dysfunction. It can develop muscle weakness. And it is kind of considered that those entities are triggered by the initial ICU admission, but they are disconnected from each other. That was kind of the feeling that dominated the conversation in long COVID, that those all those things were kind of an aggregation, an artificial aggregation, of things that were disconnected from each other in the first place. We think differently. We kind of challenged that idea. We think that if you dig deep enough, you will be able to find a common foundation of long COVID, and that is the basis of our of our research.

So, your research shows that long COVID appears to be a single disease?

Correct.

But what about the COVID virus allows it to linger in the body and cause such a wide variety of conditions?

It is possible. But if you try to detect the virus, the viral particles, or surrogates of the viral presence in the body in patients with long COVID, most of the times, you will fail to do so. So it is, I think it's going to be very difficult to substantiate the idea that the virus remains in the body as as a consequence, long COVID exists. It seems to me that there is something like a footprint left by COVID originally present in the body, and that footprint remains as a lingering abnormality that takes a long time to normalize.

So, your study shows that different patients who've experienced long COVID essentially share this same footprint. Is that correct?

That is correct.

Can you tell me about what that footprint actually is, right and how you can sort of explain it to someone who's not a COVID doctor? (laughs)

Right, absolutely. So let me tell you a very common example that we give.

Sure.

So, the information of the of the body, all the information that leads to the body, human body, as it is, is present in certain letters that are written in the DNA. That is the way the information is held by your body. However, the DNA is not a linear kind of line, or a linear change. Is something that is, you know, packed together in a very convoluted way. So, if the information is in the DNA, but is really in the center of a tangle, it will not be really visible or accessible, because it's packed, you know, in a center of something that is very complex.

So, you're looking for very small changes in DNA, which has a lot of information. So, is it looking for a needle in a haystack kind of a thing?

Absolutely, absolutely. But the important thing is that, imagine that you own the library of the world, and you were able to say, ‘I have all the information of all the books in the world,’ but in order to access a certain type of information, you need a ladder, because you wouldn't be able to find, you know, the top shelf, where some books are located. So, the information is not…what defines what the body can read, and what the what kind of information the body can have, is not only the number of books, but also the accessibility to a certain type of books. So, we investigate chemical modifications to the DNA that are not specifically on the information that the DNA has, but on changes, chemical changes associated with the DNA that define how the DNA becomes accessible. That is a phenomenon that happens due to chemical changes to the DNA, and is broadly known as an epigenetic change. So, it's not a change in the genetic information, but it's a change associated with the genetic information that decides or influences the way the genetic information can be appreciated by the body.

OK. So, is that possible, then, to look for that footprint through a simple blood test? Can you find if certain individuals may be more at risk for developing long COVID, even, maybe, before those symptoms emerge, or maybe even before they become infected by the virus in the first place?

It's a very good question that you're asking, because we do not have information as of what was the status of the patient with long COVID before the patient developed COVID, because this is the nature of the research we conduct. We don't, we cannot access a healthy person and wait for that person to become sick. It's impossible. So, you essentially enroll a patient who is complaining about the disease. So, coming to your specific point, we don't know if those changes that we are seeing in long COVID individuals are the novel, or new changes induced by the virus, or were pre-existing conditions that the patient had before the infection, and represented the susceptibility for the patient to become infected and eventually to develop long COVID. And that cannot be done with human studies. Is not really possible because you don't have, you don't have control of this pre -existent status of the patient.

But now that we've identified, or that you and your team have identified, this footprint, does that open a door, open a window, towards finding a treatment, potentially?

We don't know, because what we found is an association between a symptom, or a constellation of symptoms, and a chemical signature in those epigenetic changes in the DNA. But two things that are associated are not necessarily cause, consequence related. So, the fact that those changes occur in patients with long COVID doesn't mean that if you were able to be capable of reversing those changes, you would necessarily lead to an improvement of the symptoms, but it's a first step to at least define a biological underpinning. Because remember, like I said before, one of the challenges is that we find with those patients, is that the symptoms they have do not correlate with any organic, identifiable abnormality using the tools that the medical field has to investigate the lungs or the brains or the muscles. So at least, I feel that by finding some biological underpin, some objective entity in the circulating blood that can define a patient who has and discriminate that patient from a patient who doesn't have long COVID, is a very important first step to investigate, for example, the trajectory of those symptoms. Do those changes improve in association with the improvement of the symptoms? That is the next big question that we want, are these change in the symptoms are also going to correlate with the changes in these DNA methylation abnormalities in the blood? And things like that.
 
@Sharma Ji


Covid-19 will be with us forever - flu expert​

9:49 am on 18 August 2024

Illustration of coronavirus particles. Coronaviruses cause several diseases in humans, including covid-19, SARS and forms of the common cold. (Photo by NOBEASTSOFIERCE/SCIENCE PHOTO LI / DDJ / Science Photo Library via AFP)

Photo: AFP / NOBEASTSOFIERCE / SCIENCE PHOTO LI
It may not be the topic of many conversations now, but more than 1500 people a week are still contracting Covid-19 in New Zealand and three or four people a day are dying from it.

The virus is surging in 84 countries; and at the Olympic Games, dozens of athletes came down with it.

The World Health Organization (WHO) is worried about dangerous new variants. It is a warning we have heard before - and it comes as vaccination rates wane globally.

Dr Richard Webby: Covid-19 will be with us forever duration13′ :09″
from Sunday Morning

Dr Richard Webby: Covid-19 will be with us forever
New Zealander Dr Richard Webby is an infectious diseases researcher at the internationally recognised St Jude Children's Research Hospital in Memphis, Tennessee. He developed a vaccine for the 1997 Hong Kong avian flu outbreak, and is the director of the WHO's Collaborating Centre for Influenza studies.

He told Sunday Morning's Jim Mora that Covid-19 is now endemic.

"The word [endemic] - [and] you ask 100 different scientists what the word means and you'll get 99 different answers - but to me, it means this virus is now in a position to stay. It's going to be with us forever."

It was still a disease that could kill people, Webby said.

"It's probably a little bit less impact than the first few waves of the virus - there's probably more population immunity now, than certainly the early days.

"But you know, I'd say over the last ... two or three years, it really hasn't dropped that much at all. It has maintained a level of disease-causing capacity that surprises me a little bit."

As with any infectious disease, older people and those with underlying health issues were most at risk, he said.

"It's those folks who are least able to mount a vigorous immune response who are ... more likely to feel the effects of an infection. So whether that's Covid, whether that's flu or ... name your viral disease.

"What we're seeing with this virus is [what] we're seeing with all these others and unfortunately, this is the population that always gets the wrong end of the straw."

In terms of the disease's peak season, scientists initially thought Covid would be a winter disease, but that had not proved to be the case.

"We do seem to [be] continuing to have these summer outbreaks of Covid. Flu has settled back into [being a] winter disease now and RSV - the other part of that trio - again tags along more in the winter months, but doesn't overlap necessarily with flu season.

"We typically associate winter with all the sniffles and colds. Maybe that's not where we are any more. We've got to live with this summer version of sniffles and colds as well."
 

Doctors urging parents to get children vaccinated amid spike in COVID cases​


By Alexus Davila

August 19, 2024 / 6:47 AM EDT / CBS Baltimore

BALTIMORE -- As you get your child ready to go back to school, put vaccines on your to-do list.

Doctors are advising parents to make appointments now for your child to prevent a spike in respiratory illnesses, including COVID.

The first day of school could be a hotbed for viruses to spread because of all the summer travel and the rise in COVID cases.

But a prick on your child's arm could prevent your child from getting sick and save the lives of other family members in your household.

New covid vaccine boosters are expected to roll out later this month and in September to fight off the latest strains.

The video player is currently playing an ad.








Therefore, doctors are urging parents to call their pediatricians now.

"The new vaccines coming out right as kids are getting into school, are going to protect kids from those specific variants," AAMC Research and Action Institute Executive Director Dr. Atul Grover said.

Dr. Grover is extra worried because child vaccinations are taking a dive.

According to data from the CDC, vaccination rates among kindergarteners remain at their lowest level in decades, with only 93 percent of them vaccinated.


"That is three-quarters of a million elementary aged school kids that are going in at higher risk," Dr. Grover said.

With 35 states seeing spikes in COVID cases, Dr. Grover is also worried about the decline in COVID testing.

However, testing can be a game changer.

"We have some medications now like Tamiflu for flu and Paxlov for covid," he said. "That if you start taking those in the first couple of days of illness, it greatly diminishes your chances of both becoming severely ill and also reduces the length of time you are sick, and out of school, or out of work."

If your child rolls up their sleeves to get their vaccine, it could limit the dangerous resurgence of covid waves.

"We know that covid doesn't tend to hit them as hard. But if your kids get sick and they come back to you…as an adult and maybe a grandparent, they're more likely to get those people very, very sick."

Do not forget measles, mumps and rubella.


These illnesses have spiked this year because of the lack of vaccinations, and they can be deadly for your child.

The CDC recommends your child should get their first dose OF this when they are 12 and 15 months old.

Then a second dose between the ages of 4 and 6.
 

Long COVID has cost the Australian economy billions in lost work hours, new research says​

16h ago
A photo of the cornavirus.

The study found that in September 2022, about 1.3 million Australians were living with long COVID. (Credit: Pixabay)

In short:​

A new study has found about $9.6 billion was lost in economic productivity due to long COVID in 2022.

Researchers say that represented about a quarter of Australia's real gross domestic product growth for that year.

What's next?​

Some experts are calling on state and federal governments, as well as policymakers, to put greater focus on long COVID.
abc.net.au/news/long-covid-billions-economic-loss-australia/104234434
Link copied
Share article
Long COVID cost the Australian economy almost $10 billion in lost labour hours in 2022, according to new research.

The study, published in the peer-reviewed Medical Journal of Australia, has calculated the number of hours Australians could not work or were forced to reduce their hours as a result of ongoing COVID-19 symptoms 12 months after their diagnosis.

The research explored the number of COVID-19 infections between January 2022 to December 2023.

It found during September 2022 about 1.3 million Australians were living with long COVID and of that number about 55,000 were children aged four and under.

How many hours were lost due to long COVID?​

Researchers explored population serosurvey data from more than 5,000 working adults, and developed a mathematical model to calculate the number of ongoing COVID-19 symptoms.

The study looked at adults who had symptoms between three to 12 months, as well as those who never recovered from their illness and had symptoms for more than a year.

What is long COVID?​

According to the World Health Organization, long COVID "occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis."
Australian National University professor Quentin Grafton, who worked on the study and specialises in economics, said there were about 100 million hours lost in terms of labour.

Workers aged 30 to 49 contributed more than 50 per cent of the total labour lost.

"That has an impact not only for those people who have long COVID but on those people who look after them, care for them and their family and friends. It's an impact on the economy as a whole," he said.

"When we're talking about 10 billion that's sort of a median estimate for the losses in Australia, that works out to almost $400 per person."


Professor Grafton said governments, policymakers and workplaces needed to take much greater responsibility because the cost of long COVID was much greater than putting in place better frameworks.

"It's not a big cost, it's not trivial but it's a lower cost than the cost that we're incurring at the moment with long COVID," he said.

"It seems to me the basic economics cost benefit analysis tells us it makes sense from a social perspective, from a health perspective, public health perspective … It's time that decision makers step up."

What are some solutions?​

Researchers have estimated by December this year, there is a likelihood that between 173,000 to 873,000 Australians will still be living with long COVID a year after their initial infection — that does not include reinfection.

How do I know if I've got long COVID?​


Photo shows COVID-19 image
COVID-19 image

Scientists still don't know what causes it, how to treat it — or even how to best diagnose it. So how do we know if we have long COVID?

University of New South Wales Professor Raina MacIntyre, who specialises in epidemiology, led the study.

She said it was time for a more nuanced policy around the coronavirus, and its long-term impacts.

"I think the long-term impact is not going to be good unless we change course," she said.

"Start encouraging more people to get vaccinated, allow wider access to antivirals, take measures like safe indoor air seriously … look at situations where we do need to use masks, like in hospitals, in clinical areas."

Biosecurity expert Raina MacIntyre assesses Australia's response to the coronavirus

Professor Rainia MacIntrye said there needed to be a shift in both attitudes and policies when it came to how Australia dealt with the coronavirus. (ABC News)

Professor MacIntrye also highlighted the need for better policies on vaccination for children.

Vaccination is not currently recommended for Australian children under five years except those with medical conditions that "increases the risk of severe COVID-19 illness".

The US Centers for Disease Control and Prevention recommends COVID-19 vaccines for everyone six months and older.

Kids with long COVID want you to know they're not lying​


Photo shows An illustration shows a child with long COVID sitting alone, watching other children play in the distance
An illustration shows a child with long COVID sitting alone, watching other children play in the distance

They're losing their formative years to this debilitating disease. But for too many children with long COVID, finding help is a frustrating and traumatic process that leaves them feeling isolated and invisible.

"It's not a nothing burger in children. It is a serious infection."

She said there were simple ways to minimise risk when it came to COVID-19 infections.

"Using an air purifier, which is not very expensive, or opening a window if there is a window that can be opened, or wearing a mask," she said.

"A lot of people just say most people recover from long COVID. Well, you've got to think of it from a population health perspective, even if only 2 per cent of people have long COVID that's a major public health population health burden."
 

Pfizer (PFE), BioNTech COVID-Flu Combo Shot Study Falters​


Zacks Equity Research
Mon, Aug 19, 2024, 9:23 AM EDT3 min read

In this article:
Pfizer PFE and partner BioNTech BNTX announced that a phase III study evaluating an mRNA-based combination vaccine candidate against influenza and COVID-19 missed one of its two primary immunogenicity objectives. The vaccine combines Pfizer’s investigational mRNA-based influenza vaccine candidate with it and BioNTech’s popular marketed COVID-19 vaccine called Comirnaty. The study was conducted in more than 8000 healthy individuals aged 18-64.

The study’s two primary immunogenicity objectives were to demonstrate that the antibody responses elicited by the combination vaccine against the SARS-CoV-2 strain and influenza A and B strain were non-inferior to standard of care (“SOC”). The combination vaccine demonstrated comparable responses against the SARS-CoV-2 strain versus Comirnaty. The vaccine also demonstrated a continued trend of higher responses against influenza A. However, the combination vaccine failed to show non-inferiority against the influenza B strain in geometric mean titers and seroconversion. No new safety signals were found in the phase III study.


The companies are evaluating adjustments to their combination vaccine program to improve immune responses against influenza B and will discuss the next steps with health authorities.

BioNTech’s shares were down 2.4% on Friday in response to this news, while Pfizer’s shares were down 1.4%.

So far this year, Pfizer’s stock has declined 1.7% against an increase of 24.1% for the industry.

Zacks Investment Research

Zacks Investment Research

Image Source: Zacks Investment Research

Pfizer and BioNTech successfully paired up to give the world the most successful mRNA-based COVID-19 vaccine in 2021. Moderna MRNA also launched an mRNA-based COVID-19 vaccine, which was equally successful. Moderna is also evaluating a mRNA-based COVID/flu combination vaccine in a phase III study. In June, Moderna announced that a phase III study on its COVID/flu combination vaccine met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the study in adults 50 years and older.

Pfizer also announced data from a separate phase II study evaluating a second-generation trivalent influenza mRNA vaccine. In the study, the vaccine demonstrated robust immunogenicity against all strains compared to a SOC influenza vaccine in individuals 18-64 years of age.


Last year, Pfizer announced data from a phase III study on a first-generation quadrivalent (“qIRV”) vaccine candidate. While the mRNA vaccine demonstrated efficacy in participants 18-64 years of age, the primary endpoints for this qIRV first-generation candidate were not met in adults aged 65 and older. In order to improve immunogenicity, Pfizer developed the second-generation mRNA-based candidates. The trivalent influenza mRNA vaccine elicited robust responses against influenza A and B, including a continued trend of higher influenza A responses versus a licensed influenza vaccine.

Zacks Rank & Stock to Consider​

Pfizer has a Zacks Rank #3 (Hold) currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Pfizer Inc. Price and Consensus​

Pfizer Inc. Price and Consensus

Pfizer Inc. Price and Consensus
Pfizer Inc. price-consensus-chart | Pfizer Inc. Quote

A large drugmaker worth considering is Eli Lilly LLY, carrying a Zacks Rank of 2 (Buy). Year to date, Lilly’s stock has risen 58.2%. Earnings estimates for 2024 have risen from $13.71 to $15.77 per share over the past 30 days. For 2025, earnings estimates have risen from $19.42 to $22.79 per share over the same timeframe.

The healthcare bellwether’s performance has been solid, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 69.07%, on average. In the last reported quarter, the company delivered an earnings surprise of 48.48%
 

Users who are viewing this thread

Pakistan Defence Latest

Back
Top